Physician profile
Charles Corbett
NPI 1619039526
$7,974.42
in general payments reported to CMS, 2019-2025
21 companies · $834 in 2025
The $834 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $1,539 · 2021: $1,732 · 2022: $943 · 2023: $955 · 2024: $1,035 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,603.81 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,516.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $1,008.79 | 2019-2023 | |
| Glaxosmithkline, LLC. | $550.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $503.50 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $444.51 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $429.11 | 2019-2023 | |
| Abbott Laboratories | $345.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.11 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $313.81 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $195.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.86 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $149.08 | 2020-2023 | Xarelto |
| Exact Sciences Corporation | $105.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $104.00 | 2020-2025 | Repatha, Otezla, Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $66.18 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $63.99 | 2024-2025 | Keveyis |
| Abbvie INC. | $23.35 | 2025 | |
| Allergan, INC. | $15.68 | 2020 | |
| Dermira, INC. | $12.40 | 2020 | |
| Horizon Therapeutics Plc | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.